GE HealthCare Q4 revenue $4.9B, adj EPS $1.31; FY23 adj EPS guidance $3.60-$3.75

GE HealthCare Technologies Inc.

2023-FY EPS reported $4.22 revenue$18,341,000,000

Q4 revenue $4.9B (+8% reported, +13% organic); net income $554M, EPS $1.21, adjusted EPS $1.31.
FY22 revenue $18.3B (+4% reported, +7% organic); net income $1.9B, EPS $4.18, adjusted EPS $4.63.
FY23 guidance: organic revenue growth 5-7%, adj EBIT margin 15.0-15.5%, adj EPS $3.60-$3.75, FCF conversion 85%+.
Cash from operations $2.1B, free cash flow $1.8B for FY22; cash conversion 111%.
Announced agreement to acquire IMACTIS to strengthen interventional guidance capabilities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GE HealthCare Technologies Inc. reported Fourth quarter and full year ended December 31, 2022 results: revenue Revenues of $4.9 billion, net income Net income was $554 million, EPS Earnings per share (EPS) from continuing operations were $1.21. Guidance reaffirmed.

Period: Fourth quarter and full year ended December 31, 2022
Revenue: Revenues of $4.9 billion
Net income: Net income was $554 million
EPS: Earnings per share (EPS) from continuing operations were $1.21
Guidance: reaffirmed
Result: reported results

Exact text from the filing

access to care, and an aging population globally. We are well positioned to deliver on our 2023 commitments.” Fourth quarter 2022 total financial performance • Revenues of $4.9 billion increased 8% and 13% on an Organic basis* year-over-year, driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound. Acquisitions favorably impacted total revenue

View on SEC.gov

Browse all earnings releases →

GE HealthCare Technologies Inc. filing history →

Source: SEC EDGAR

accession 0001932393-23-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.